52632-05-0

Basic information

• Product Name: 2-(P-DIMETHYLAMINOPHENYL)ETHYLAMINE
• Synonyms: 4-N,N-Dimethylaminophenethylamine;Benzeneethanamine, 4-(dimethylamino)-;Dmapea;4-(2-aminoethyl)-N,N-dimethylaniline(SALTDATA: FREE);2-(4-DiMethylaMinophenyl)ethylaMine;4-(dimethylamino)Benzeneethanamine;Phenethylamine, p-(dimethylamino)-;AKOS BB-9234
• CAS NO: 52632-05-0
• Molecular Formula: C₁₀H₁₆N₂
• Molecular Weight: 164.25
• Mol File: 52632-05-0.mol

Chemical Properties

• Boiling Point: 275.8 °C at 760 mmHg
• Flash Point: 108.3 °C
• Appearance: /
• Density: 1.002 g/cm³
• Vapor Pressure: 0.00499mmHg at 25°C
• Refractive Index: 1.568
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 10.37±0.10(Predicted)
• CAS DataBase Reference: 2-(P-DIMETHYLAMINOPHENYL)ETHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(P-DIMETHYLAMINOPHENYL)ETHYLAMINE(52632-05-0)
• EPA Substance Registry System: 2-(P-DIMETHYLAMINOPHENYL)ETHYLAMINE(52632-05-0)

Safety Data

• Hazard Codes: Xi
• Statements: 43
• Safety Statements: 36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 52632-05-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
2-(P-DIMETHYLAMINOPHENYL)ETHYLAMINE is used as a research chemical for studying the effects of psychoactive substances on the central nervous system. Its structural similarity to amphetamine and mescaline makes it a valuable tool for understanding the mechanisms of action and potential therapeutic applications of these compounds.
Used in Forensic Toxicology:
2-(P-DIMETHYLAMINOPHENYL)ETHYLAMINE is utilized as a reference substance in forensic toxicology to identify and analyze its presence in biological samples, aiding in the investigation of cases involving drug abuse and overdose.
Used in Public Health and Safety Initiatives:
2-(P-DIMETHYLAMINOPHENYL)ETHYLAMINE is employed in public health and safety initiatives to raise awareness about the dangers of recreational drug use, particularly highlighting the risks of overdose and serious side effects associated with PMA.

InChI:InChI=1/C10H16N2/c1-12(2)10-5-3-9(4-6-10)7-8-11/h3-6H,7-8,11H2,1-2H3

Upstream product

• 34906-70-2 (4-dimethylamino-phenyl)-acetonitrile 
• 2604-08-2 1-nitro-2-(4'-dimethylaminophenyl)ethene 
• 1164369-29-2 C₁₅H₂₄N₂O₂ 
• 524743-26-8 2-[2-(4-N,N-dimethylaminophenyl)-ethyl]-isoindole-1,3-dione 
• 100-10-7 4-dimethylamino-benzaldehyde 
• 3544-25-0 p-aminophenylacetonitrile 
• 64-17-5 ethanol 
• 73718-09-9 3-[4-(dimethylamino)phenyl]propanoic acid 
• 22568-06-5 (E)-N,N-dimethyl-4-(2-nitrovinyl)aniline 

Downstream Products

• 27389-67-9 trimethyl-(4-trimethylammonio-phenethyl)-ammonium; diiodide 

Relevant articles and documents

Design, synthesis, and biological evaluation of novel EGFR inhibitors containing 5-chloro-3-hydroxymethyl-indole-2-carboxamide scaffold with apoptotic antiproliferative activity

New EGFR inhibitor series of fifteen 5-chloro-3-hydroxymethyl-indole-2-carboxamide derivatives has been designed, synthesized, and tested for antiproliferative activity against a panel of cancer cell lines. The results showed that p-substituted phenethyl derivatives 10, 11, 13, 15 and 17–19 showed superior antiproliferative activity compared to their m-substituted counterparts 12, 14, 16 and 20. Compounds 15, 16, 19 and 20 displayed promising EGFR inhibitory activity as well as an increase in caspase 3 levels. Compounds 15 and 19 increased caspase-8 and 9 levels, as well as inducing Bax and decreasing Bcl-2 protein levels. Compound 19 demonstrated cell cycle arrest at pre-G1 and G2/M phases. The results of the docking study into the active site of EGFR revealed strong fitting of the new compounds with higher binding affinities compared to erlotinib.

Novel 1,5-diaryl pyrazole-3-carboxamides as selective COX-2/sEH inhibitors with analgesic, anti-inflammatory, and lower cardiotoxicity effects

COX-2 selective drugs have been withdrawn from the market due to cardiovascular side effects, just a few years after their discovery. As a result, a new series of 1,5-diaryl pyrazole carboxamides 19–31 was synthesized as selective COX-2/sEH inhibitors wit

Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAFV600E dual inhibitors

Recent studies have shown additive and synergistic effects associated with the combination of kinase inhibitors. BRAFV600E and EGFR are attractive targets for many diseases treatments and have been studied extensively. In keeping with our interest in developing anticancer targeting EGFR and BRAFV600E, a novel series of 2,3-dihydropyrazino[1,2-a]indole-1,4-dione has been rationally designed, synthesized and evaluated for their antiproliferative activity against a panel of four human cancer cell lines. Compounds 20–23, 28–31, and 33 showed promising antiproliferative activities. These compounds were further tested for their inhibitory potencies against EGFR and BRAFV600E kinases with erlotinib as a reference drug. Compounds 23 and 33 exhibited equipotency to doxorubicin against the four cell lines and efficiently inhibited both EGFR (IC50 = 0.08 and 0.09 μM, respectively) and BRAFV600E (IC50 = 0.1 and 0.29 μM, respectively). In cell cycle study of MCF-7 cell line, compounds 23 and 33 induced apoptosis and exhibited cell cycle arrest in both Pre-G1 and G2/M phases. Molecular docking analyses revealed that the new compounds can fit snugly into the active sites of EGFR, and BRAFV600E kinases. Compound 23, 31 and 33 adopted similar binding orientations and interactions to those of erlotinib and vemurafenib.

Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric Oxide Synthase Inhibitors

Neuronal nitric oxide synthase (nNOS) is a target for development of antineurodegenerative agents. Most nNOS inhibitors mimic l-arginine and have poor bioavailability. 2-Aminoquinolines showed promise as bioavailable nNOS inhibitors but suffered from low

Design, synthesis and pharmacophoric model building of new 3-alkoxymethyl/3-phenyl indole-2-carboxamides with potential antiproliferative activity

Novel 3-alkoxymethyl/3-phenyl indole-2-carboxamide derivatives were synthesized and evaluated for their anticancer activity. Most of the tested compounds showed moderate to excellent activity against the tested cell lines (MCF7 and HCT116). 3-Phenyl substitution on indole with p-piperidinyl phenethyl 24a and p-dimethylamino phenethyl 24c exhibited anticancer activity against MCF7 with IC50 of 0.13 and 0.14?μm, respectively. Further mechanistic study of the most active compounds through their action on cell cycle showed disturbance in cell cycle progression and cell cycle arrest. For future development of this series of compounds, pharmacophore study was conducted which indicated that the enhancement of the activity could be achieved through the addition of acceptor or donating groups to the already-present indole nucleus.

Synthesis, biological evaluation, docking study and ulcerogenicity profiling of some novel quinoline-2-carboxamides as dual COXs/LOX inhibitors endowed with anti-inflammatory activity

A series of novel quinoline-2-carboxamides 15–28 was synthesized and evaluated in?vitro as dual COXs/LOX inhibitors. Compounds 19 and 27 exhibited the highest potency and selectivity for COX-2 inhibitory activity (IC50?=?1.21 and 1.13?μM, respe

Hydantoin and thiohydantoin derivatives as antiviral drugs

The present invention relates to a compound of the following formula (I), or a salt, solvate, tautomer, enantiomer, diastereoisomer or racemic mixture thereof: as well as its use as a drug, notably in the treatment of hepatitis C, its preparation process, and the pharmaceutical compositions containing such a compound.

HYDANTOIN AND THIOHYDANTOIN DERIVATIVES AS ANTIVIRAL DRUGS

The present invention relates to a compound of the following formula (I), or a salt, solvate, tautomer, enantiomer, diastereoisomer or racemic mixture thereof: as well as its use as a drug, notably in the treatment of hepatitis C, its preparation process, and the pharmaceutical compositions containing such a compound.

Synthesis and activity of N-oxalylglycine and its derivatives as Jumonji C-domain-containing histone lysine demethylase inhibitors

N-Oxalylglycine (NOG) derivatives were synthesized, and their inhibitory effect on histone lysine demethylase activity was evaluated. NOG and compound 1 inhibited histone lysine demethylases JMJD2A, 2C and 2D in enzyme assays, and their dimethyl ester prodrugs DMOG and 21 exerted histone lysine methylating activity in cellular assays.

SULFONYLBENZODIAZEPINONE ACETAMIDES AS BRADYKININ ANTAGONISTS

Disclosed are compounds, of formula (I) which are bradykinin antagonists and are useful to treat diseases or relieve adverse symptoms associated with disease conditions in mammals mediated by bradykinin. Certain of the compounds exhibit increased potency and are expected to also exhibit an increased duration of action.